menu

Should We Make Active Surveillance More Active for Localized Prostate Cancer?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Prostate Cancer: Focusing Androgen Receptor Inhibitors on High-Risk Localized & Locally Advanced Disease

Should We Make Active Surveillance More Active for Localized Prostate Cancer?

MinuteCE®
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.

  • Target Audience

    This activity has been designed to meet the educational needs of interprofessional teams, including oncologists, urologists, radiologists, and other team members, which are involved in the management of patients with prostate cancer.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Describe the risk of developing metastases and cancer-related mortality based on risk stratification in localized prostate cancer
    • Assess the evolving changes in guideline recommendations for high-risk localized and locally advanced prostate cancer and where ARIs fit into these recommendations
    • Evaluate the efficacy and safety of second-generation ARI therapy in patients with newly diagnosed prostate cancer who have high-risk localized or locally advanced disease
    • Employ effective multidisciplinary adverse effect management strategies to improve ARI treatment adherence
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Rana R. McKay, MD, faculty for this educational event, receives a research funds from Bayer, AstraZeneca, BMS, Tempus, Exelixis, Oncternal, and Artera; and receives consulting fees for AstraZeneca, Aveo, Bayer, BMS, Calithera, Caris, Dendreon, Exelixis, Eisai, JNJ, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Sorrento Therapeutics, Tempus, and Telix. 

    Neeraj Agarwal, MD, FASCO, faculty for this educational event, receives research funds from Arnivas, Astellas, Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon; and receives consulting fees Astellas, Astra Zeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    Megan Reimann, PharmD, BCOP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    Total CME, LLC., planners, and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go, you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    Supported by an independent educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. 

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Instructions for Completion

    During the period 8/18/2023 through 8/18/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule12 Jun 2024